<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.journal-inflammation.com/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Journal of Inflammation - Latest Articles</title>
        <link>http://www.journal-inflammation.com</link>
        <description>The latest research articles published by Journal of Inflammation</description>
        <dc:date>2013-05-24T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/10/1/22" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/10/1/21" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/10/1/20" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/10/1/19" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/10/1/18" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/10/1/17" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/10/1/16" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/10/1/15" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/10/1/14" />
                                <rdf:li rdf:resource="http://www.journal-inflammation.com/content/10/1/13" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.journal-inflammation.com/content/10/1/22">
        <title>Increased serum complement C3 and C4 concentrations and their relation to severity of chronic spontaneous urticaria and CRP concentration</title>
        <description>Chronic spontaneous urticaria (CU) is associated with activation of the acute phase response (APR). Nevertheless, APR-associated proteins have not been well characterized as potential biomarkers of the disease severity. To assess the pattern of complement proteins C3 and C4 -- the acute phase reactants in patients with CU. C3, C4 and CRP concentrations were measured in serum of 70 patients showing different degrees of urticarial severity as well as in 33 healthy subjects. Serum C3 and C4 concentrations were significantly increased in CU patients as compared with the healthy subjects and exceed the normal lab range by about 5% and 10%, respectively. Significant differences were found between patients with mild and increased CU severity. In addition, significant correlations were observed between C3, C4 and CRP concentrations. More severe CU is characterized by higher production of C3 and C4 complements accompanied by parallel changes in CRP concentration.</description>
        <link>http://www.journal-inflammation.com/content/10/1/22</link>
                <dc:creator>Alicja Kasperska-Zajac</dc:creator>
                <dc:creator>Alicja Grzanka</dc:creator>
                <dc:creator>Edyta Machura</dc:creator>
                <dc:creator>Maciej Misiolek</dc:creator>
                <dc:creator>Bogdan Mazur</dc:creator>
                <dc:creator>Jerzy Jochem</dc:creator>
                <dc:source>Journal of Inflammation 2013, null:22</dc:source>
        <dc:date>2013-05-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-10-22</dc:identifier>
                                <prism:require>/content/figures/1476-9255-10-22-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>22</prism:startingPage>
        <prism:publicationDate>2013-05-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/10/1/21">
        <title>Transient expansion of activated CD8+ T cells characterizes tuberculosis-associated immune reconstitution inflammatory syndrome in patients with HIV: a case control study</title>
        <description>Background:
CD4+ T cell activation indicators have been reported to be a common phenomenon underlying diverse manifestations of immune reconstitution inflammatory syndrome (IRIS). However, we have found that a high frequency of circulating CD8+ T cells is a specific risk factor for mycobacterial IRIS. Therefore, we investigated whether CD8+ T cells from patients who develop TB IRIS were specifically activated.MethodsWe obtained PBMCs from HIV + patients prior to and 4, 8, 12, 24, 52 and 104 weeks after initiating antiretroviral therapy. CD38 and HLADR expression on naive, central memory and effector memory CD8+ and CD4+ T cells were determined by flow cytometry. Absolute counts and frequencies of CD8+ T cell subsets were compared between patients who developed TB IRIS, who developed other IRIS forms and who remained IRIS-free.
Results:
TB IRIS patients showed significantly higher counts of naive CD8+ T cells than the other groups at most time points, with a contraction of the effector memory subpopulation occurring later in the follow-up period. Activated (CD38+ HLADR+) CD8+ T cells from all groups decreased with treatment but transiently peaked in TB IRIS patients. This increase was due to an increase in activated naive CD8+ T cell counts during IRIS. Additionally, the CD8+ T cell subpopulations of TB IRIS patients expressed HLADR without CD38 more frequently and expressed CD38 without HLADR less frequently than cells from other groups.
Conclusions:
CD8+ T cell activation is specifically relevant to TB IRIS. Different IRIS forms may involve different alterations in T cell subsets, suggesting different underlying inflammatory processes.</description>
        <link>http://www.journal-inflammation.com/content/10/1/21</link>
                <dc:creator>Enrique Espinosa</dc:creator>
                <dc:creator>Dámaris Romero-Rodríguez</dc:creator>
                <dc:creator>María-Teresa Cantoral-Díaz</dc:creator>
                <dc:creator>Gustavo Reyes-Terán</dc:creator>
                <dc:source>Journal of Inflammation 2013, null:21</dc:source>
        <dc:date>2013-05-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-10-21</dc:identifier>
                                <prism:require>/content/figures/1476-9255-10-21-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>21</prism:startingPage>
        <prism:publicationDate>2013-05-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/10/1/20">
        <title>MicroRNA-146 inhibits pro-inflammatory cytokine secretion through IL-1 receptor-associated kinase 1 in human gingival fibroblasts</title>
        <description>Background:
Although various microRNAs (miRNAs) regulate immune and inflammatory responses, the function of miRNAs in periodontitis has not been clearly illuminated. In this study, we measured miRNA-146 (miRNA-146a and miRNA-146b-5p) expression and explored its regulatory function in the inflammatory response in human gingival fibroblasts (HGFs).
Methods:
miRNA-146a and miRNA-146b-5p expression was measured by performing real-time polymerase chain reaction in HGFs after Porphyromonas gingivalis (p.g) lipopolysaccharide (LPS) stimulation. After the HGFs were transfected with miRNA-146a and miRNA-146b-5p inhibitor, the expression levels of interleukin-1&#946; (IL-1&#946;), interleukin-6 (IL-6) and tumor necrosis factor-&#945; (TNF-&#945;) were measured by enzyme-linked immunosorbent assay (ELISA). Meanwhile, IL-1 receptor-associated kinase 1 (IRAK1) and TNF receptor-associated factor 6 (TRAF6) were detected by western blot and quantitative PCR. A luciferase assay was used to detect whether miRNA-146 could directly bind to the 3&#8217;-UTR of IRAK1.
Results:
The expression levels of miRNA-146a and miRNA-146b-5p significantly increased in the P.g LPS-stimulated HGFs compared to the non-stimulated HGFs. The inhibition of miRNA-146a and miRNA-146b-5p resulted in increased IL-1&#946;, IL-6 and TNF-&#945; secretion. The mRNA and protein levels of IRAK1, but not TRAF6, also increased. We further found that miRNA-146a and miRNA-146b-5p directly bound to the IRAK1 3&#8217;-UTR.
Conclusion:
Our data suggest that miRNA-146 inhibits pro-inflammatory cytokine secretion through IRAK1 in HGFs, which indicates that miRNA-146 functions as a negative regulator of periodontal inflammation.</description>
        <link>http://www.journal-inflammation.com/content/10/1/20</link>
                <dc:creator>Yu-Feng Xie</dc:creator>
                <dc:creator>Rong Shu</dc:creator>
                <dc:creator>Shao-Yun Jiang</dc:creator>
                <dc:creator>Da-Li Liu</dc:creator>
                <dc:creator>Jing Ni</dc:creator>
                <dc:creator>Xiu-Li Zhang</dc:creator>
                <dc:source>Journal of Inflammation 2013, null:20</dc:source>
        <dc:date>2013-05-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-10-20</dc:identifier>
                                <prism:require>/content/figures/1476-9255-10-20-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>20</prism:startingPage>
        <prism:publicationDate>2013-05-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/10/1/19">
        <title>TRPM2 channels are not required for acute airway inflammation in OVA-induced severe allergic asthma in mice</title>
        <description>Background:
Airway inflammation and asthma have been linked to oxidative stress and the melastatin-related transient receptor potential cation channel, member 2 (TRPM2), which can be activated by reactive oxygen species (ROS), has emerged as a potential therapeutic target for inflammatory diseases.ObjectiveUsing TRPM2 deficient (TRPM2-/-) mice, we investigated whether the TRPM2 ion channel, which mediates calcium (Ca2+) influx and lysosomal Ca2+ release, plays a role in the pathophysiology of severe allergic asthma in mouse.
Methods:
Severe allergic asthma was initiated in wild type (WT) and TRPM2-/- mice by repeated sensitization with ovalbumin (OVA)/aluminum hydroxide on Days 0, 7 and 14, followed by intranasal challenge on Days 21, 22 and 23. Mice were investigated for the presence of airway responsiveness, airway inflammation, production of allergen-specific antibodies, cytokine response and lung pathology.
Results:
The absence of TRPM2 channels has no obvious effect on major etiologic markers of severe allergic asthma in this mouse model. Neither airway resistance nor mucus production are affected in TRPM2-/- mice. TRPM2 channel ablation also does not alter airway inflammation or immunocyte infiltration and does not affect antibody response or cytokine levels.
Conclusions:
TRPM2 is not required for airway inflammation in OVA-induced severe allergic asthma in mice. Accordingly, TRPM2 might not be a suitable therapeutic target for airway inflammation caused by allergens in humans.</description>
        <link>http://www.journal-inflammation.com/content/10/1/19</link>
                <dc:creator>Adriana Sumoza-Toledo</dc:creator>
                <dc:creator>Andrea Fleig</dc:creator>
                <dc:creator>Reinhold Penner</dc:creator>
                <dc:source>Journal of Inflammation 2013, null:19</dc:source>
        <dc:date>2013-05-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-10-19</dc:identifier>
                                <prism:require>/content/figures/1476-9255-10-19-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>19</prism:startingPage>
        <prism:publicationDate>2013-05-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/10/1/18">
        <title>Transcription networks responsible for early regulation of Salmonella-induced inflammation in the jejunum of pigs</title>
        <description>Background:
The aim of this study was to identify transcription factors/regulators that play a crucial role in steering the (innate) immune response shortly (within a few hours) after the first contact of the intestinal mucosa with an inflammatory mediator, and to test whether the processes regulated by these factors/regulators can be modulated by chemical substances of natural origin.
Methods:
We experimentally induced inflammation by perfusion of surgically applied jejunal loops with Salmonella enterica subspecies enterica serovar Typhimurium DT104 in three pigs. Segments of mock and Salmonella treated loops were dissected after 2, 4 and 8&#8201;hours of perfusion. IL8 and IL1-beta mRNA expression levels were measured in mucosal scrapings of all segments. Furthermore, intra-animal microarray comparisons (isogenic) between Salmonella and mock treated segments after 8&#8201;hours, and inter-animal comparisons between similar Salmonella-treated loops of each pig at 2 and 4&#8201;hours, were performed.
Results:
IL-1beta and IL8 mRNA levels, and intra-animal microarray comparisons at 8&#8201;hours between Salmonella and mock treated segments showed that the response-time and type of response to Salmonella was different in all three pigs. This plasticity allowed us to extract a comprehensive set of differentially expressed genes from inter-animal comparisons at 2 and 4&#8201;hours. Pathway analysis indicated that many of these genes play a role in induction and/or tempering the inflammatory response in the intestine. Among them a set of transcription factors/regulators known to be involved in regulation of inflammation, but also factors/regulators for which involvement was not expected. Nine out of twenty compounds of natural origin, which according to literature had the potential to modulate the activity of these factors/regulators, were able to stimulate or inhibit a Salmonella-induced mRNA response of inflammatory-reporter genes IL8 and/or nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor alpha in cultured intestinal porcine epithelial cells.
Conclusions:
We describe a set of transcription factors/regulators possibly involved in regulation of &#8220;very early&#8221; immune mechanism which determines the inflammatory status of the intestine later on. In addition, we show that these mechanisms may be modulated by chemical substances of natural origin.</description>
        <link>http://www.journal-inflammation.com/content/10/1/18</link>
                <dc:creator>Marcel Hulst</dc:creator>
                <dc:creator>Mari Smits</dc:creator>
                <dc:creator>Stéphanie Vastenhouw</dc:creator>
                <dc:creator>Agnes de Wit</dc:creator>
                <dc:creator>Theo Niewold</dc:creator>
                <dc:creator>Jan van der Meulen</dc:creator>
                <dc:source>Journal of Inflammation 2013, null:18</dc:source>
        <dc:date>2013-04-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-10-18</dc:identifier>
                                <prism:require>/content/figures/1476-9255-10-18-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>18</prism:startingPage>
        <prism:publicationDate>2013-04-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/10/1/17">
        <title>MALP-2 pre-treatment modulates systemic inflammation in hemorrhagic shock</title>
        <description>Background:
TLR-2 is expressed on the surface of leucocytes, lung and liver tissue and initiates the activation of immune response after interaction with components of the bacterial cell wall. In this experiment we investigated whether immunostimulation with TLR-2 agonists under conditions of sterile inflammation (hemorrhagic shock (HS)) may affect the immune response and remote organ inflammation.
Methods:
Male C57/BL6 mice were subjected to standardized pressure-controlled HS (MAP of 35 mmHg for 90 minutes). The TLR-2 agonist macrophage-activated lipopeptide-2 (MALP-2) was administered (i.p.) either 12 hours prior to the induction of HS (Group MALP PT) or after the hypotensive period (90 minutes) (Group MALP T). After six hours, plasma cytokine levels (IL-6, KC, IL-10, and MCP-1) and lung and liver MPO activity were assessed.
Results:
Pre-treatment with MALP-2 resulted in a significant attenuation of the systemic pro-inflammatory (IL-6) response (MALP PT: 0.83&#177;0.2 ng/ml vs. MALP T: 1.7&#177;0.09 ng/ml) (p&lt;0.05). In comparison to the liver MPO activity, lung MPO levels in in group MALP PT did not show differences to levels measured in MALP T mice (1.200&#177;200 ng/mg vs. 1.800&#177;200 ng/mg).
Conclusions:
After initial inflammation, MALP-2 pre-treatment was associated with attenuated systemic immune response after sterile stimulus. The TLR-2 agonist appears to affect sterile inflammation pathways. The exact mechanisms should be studied further to better understand these affects.</description>
        <link>http://www.journal-inflammation.com/content/10/1/17</link>
                <dc:creator>Roman Pfeifer</dc:creator>
                <dc:creator>Thomas Tschernig</dc:creator>
                <dc:creator>Philipp Lichte</dc:creator>
                <dc:creator>Derek Dombroski</dc:creator>
                <dc:creator>Philipp Kobbe</dc:creator>
                <dc:creator>Hans-Christoph Pape</dc:creator>
                <dc:source>Journal of Inflammation 2013, null:17</dc:source>
        <dc:date>2013-04-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-10-17</dc:identifier>
                                <prism:require>/content/figures/1476-9255-10-17-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>17</prism:startingPage>
        <prism:publicationDate>2013-04-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/10/1/16">
        <title>Bioluminescence imaging for IL-1beta expression in experimental colitis</title>
        <description>Background:
Interleukin 1 beta (IL-1&#946;) contributes to the development of inflammatory bowel disease (IBD) and is correlated with the severity of intestinal inflammation. However, the precise source of IL-1&#946; producing cells in DSS colitis is currently not known.
Methods:
To determine IL-1&#946; activity during intestinal inflammation in real time, an IL-1&#946; transgenic mouse has been generated by incorporating the firefly luciferase gene driven by a 4.5-kb fragment of human IL-1&#946; gene promoter (named cHS4I-hIL-1&#946;P-Luc transgenic mice). Dextran sodium sulfate (DSS) induced colitis was confirmed with clinical presentation and histopathology.
Results:
A substantial increase in luciferase activity (reflecting IL-1&#946; production) in the region of inflamed colon was observed in a time dependent manner, followed by additional activity in the region of the mesenteric lymph node. The up-regulated luciferase activity was suppressed by dexamethasone (steroids) during DSS challenge, consistent with reduced severity of colitis, confirming the specificity of luciferase activity.
Conclusions:
Our data suggests that bioluminescence is an interesting technology, which may be used to evaluate transcription of various genes in real time in experimental colitis.</description>
        <link>http://www.journal-inflammation.com/content/10/1/16</link>
                <dc:creator>Limei Li</dc:creator>
                <dc:creator>Zhenzhe Liu</dc:creator>
                <dc:creator>Xinyu Yang</dc:creator>
                <dc:creator>Huimin Yan</dc:creator>
                <dc:creator>Shisan Bao</dc:creator>
                <dc:creator>Jian Fei</dc:creator>
                <dc:source>Journal of Inflammation 2013, null:16</dc:source>
        <dc:date>2013-04-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-10-16</dc:identifier>
                                <prism:require>/content/figures/1476-9255-10-16-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>16</prism:startingPage>
        <prism:publicationDate>2013-04-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/10/1/15">
        <title>Histone deacetylase inhibitors up-regulate LL-37 expression independent of toll-like receptor mediated signalling in airway epithelial cells</title>
        <description>HDAC inhibitors have been proposed as anticancer agents. However, their roles in innate genes expression remain not well known. Cathelicidin LL-37 is one of the few human bactericidal peptides, but the regulation of histone acetylation on LL-37 expression in airway epithelium remains largely unknown. Therefore, we investigated the effects of two non-selective HDACi, trichostatin A (TSA) and sodium butyrate (SB), on the expression of the cathelicidin LL-37 in human airway epithelial cells. LL37 in human NCI-H292 airway epithelial cells and the primary cultures of normal nasal epithelial cells(PNEC) in response to HDAC inhibitors with or without poly (I:C) stimulation was assessed using real-time PCR and western blot. In parallel, IL-6 expression was evaluated by ELISA. Our results showed that HDAC inhibitors up-regulated LL-37 gene expression independent of poly (I:C) stimulation in PNEC as well as in NCI-H292 cells. HDAC inhibitors increased LL37 protein expression in NCI-H292 cells but not in PNEC. In addition, HDAC inhibitors significantly inhibited poly (I:C)-induced IL-6 production in both of the epithelial cells. In conclusion, HDAC inhibitors directly up-regulated LL-37 gene expression in human airway epithelial cells.</description>
        <link>http://www.journal-inflammation.com/content/10/1/15</link>
                <dc:creator>Quan Liu</dc:creator>
                <dc:creator>Juan Liu</dc:creator>
                <dc:creator>Kristina Irene Lisolette Roschmann</dc:creator>
                <dc:creator>Danielle van Egmond</dc:creator>
                <dc:creator>Korneliusz Golebski</dc:creator>
                <dc:creator>Wytske Fokkens</dc:creator>
                <dc:creator>Dehui Wang</dc:creator>
                <dc:creator>Cornelis van Drunen</dc:creator>
                <dc:source>Journal of Inflammation 2013, null:15</dc:source>
        <dc:date>2013-04-11T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-10-15</dc:identifier>
                                <prism:require>/content/figures/1476-9255-10-15-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>15</prism:startingPage>
        <prism:publicationDate>2013-04-11T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/10/1/14">
        <title>The anti-idiotypic antibody 1F7 stimulates monocyte interleukin-10 production and induces endotoxin tolerance</title>
        <description>Background:
Pathogens that establish chronic infection elicit immune responses with suppressive cytokines dominating over pro-inflammatory cytokines. Chronic hepatitis C virus (HCV) infection, human immunodeficiency virus (HIV) infection and simian immunodeficiency virus (SIV) infection are associated with high levels of antiviral antibodies expressing a common idiotype specifically recognized by the 1F7 monoclonal antibody (mAb). The 1F7 mAb is a murine IgM&#954; antibody raised against immunoglobulin pooled from the plasma of multiple HIV-infected individuals. In this study, we investigated direct effects of the 1F7 mAb itself on peripheral blood mononuclear cells (PBMC).
Methods:
Isolated monocytes or PBMC from healthy controls were incubated with the 1F7 mAb or IgM&#954; mAb control. Cytokine production was measured in cell culture supernatants by ELISA and cells producing interleukin-10 (IL-10) were identified by subset depletion and intracellular flow cytometry. Endotoxin tolerance was assessed by exposing monocytes to lipopolysaccharide (LPS) following 1F7 mAb or IgM&#954; mAb control pre-treatment and comparing tumor necrosis factor (TNF)-&#945; levels in cell culture supernatants.
Results:
The 1F7 mAb stimulated monocytes and CD36+ lymphocytes to produce IL-10 in a time and dose-dependent manner. Treatment of monocytes with 1F7 mAb also reduced their subsequent responsiveness to LPS stimulation.
Conclusions:
Induction of antibodies expressing the 1F7 idiotype by chronic pathogens may facilitate IL-10 production and progression to chronic infection. Direct effects of IL-10 from human monocytes stimulated by 1F7-like antibodies, followed by monocyte transition to an alternatively activated phenotype illustrated by endotoxin tolerance, are two complementary features favouring a tolerogenic or non-responsive immunological environment.</description>
        <link>http://www.journal-inflammation.com/content/10/1/14</link>
                <dc:creator>Tigran Davtyan</dc:creator>
                <dc:creator>David Poghosyan</dc:creator>
                <dc:creator>Anna Sukiasyan</dc:creator>
                <dc:creator>Michael Grant</dc:creator>
                <dc:source>Journal of Inflammation 2013, null:14</dc:source>
        <dc:date>2013-04-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-10-14</dc:identifier>
                                <prism:require>/content/figures/1476-9255-10-14-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>14</prism:startingPage>
        <prism:publicationDate>2013-04-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.journal-inflammation.com/content/10/1/13">
        <title>Treatment for sleep apnea by continuous positive airway pressure improves levels of inflammatory markers - a meta-analysis</title>
        <description>Background:
Obstructive sleep apnea (OSA) is associated with coronary artery disease (CAD). Intermittent hypoxia associated with OSA increases sympathetic activity and may cause systemic inflammation, which may contribute to CAD in patients with OSA. Treatment with continuous positive airway pressure (CPAP) has been shown to change levels of inflammatory markers. We analyzed data from published studies by a systematic meta-analysis.ObjectiveTo asses if treatment for sleep apnea by CPAP will affect levels of inflammatory markers.Data resourcesPubMed, Embase and Cochrane library.
Methods:
Study eligibility criteria full text English studies of adult, human subjects, addressing values of at least one of the inflammatory markers before and after CPAP treatment. We used the definition of OSA as an apnea-hypopnea index (AHI) of&#8201;&#8805;&#8201;5/h, reported values in mean and standard deviation or median with range.ParticipantsAdult, human.InterventionsCPAP treatment for OSA.Study appraisal and synthesis methodA total of 3835 studies were reviewed for inclusion, while 23 studies pooled for analysis. A total of 14 studies with 771 patients were pooled for C-reactive protein (CRP); 9 studies with 209 patients were pooled for tumor necrosis factor-alpha (TNF-&#945;); and 8 studies with 165 patients were pooled for interleukin-6 (IL-6).Endpoint definitionsThe following inflammatory markers were chosen: CRP, TNF-&#945;, and IL-6.
Results:
C-reactive protein: Study level means ranged from 0.18 to 0.85&#160;mg/dl before CPAP treatment and 0.10 to 0.72&#160;mg/dl after CPAP treatment. Mean differences, at a study level, ranged from &#8722;0.05 to 0.50. The pooled mean difference was 0.14 [95% confidence interval 0.08 to 0.20, p&#8201;&lt;&#8201;0.00001]. There was heterogeneity in this endpoint (df&#8201;=&#8201;13, p&#8201;&lt;&#8201;0.00001, I2&#8201;=&#8201;95%).Tumor necrosis factor-&#945;: Study level means ranged from 1.40 to 50.24&#160;pg/ml before CPAP treatment and 1.80 to 28.63&#160;pg/ml after CPAP treatment. Mean differences, at a study level, ranged from &#8722;1.23 to 21.61. The pooled mean difference was 1.14 [95% confidence interval 0.12 to 2.15, p&#8201;=&#8201;0.03]. There was heterogeneity in this endpoint (df&#8201;=&#8201;8, p&#8201;&lt;&#8201;0.00001, I2&#8201;=&#8201;89%).Interleukin-6: Study level means ranged from 1.2 to 131.66&#160;pg/ml before CPAP treatment and 0.45 to 66.04&#160;pg/ml after CPAP treatment. Mean differences, at a study level, ranged from &#8722;0.40 to 65.62. The pooled mean difference was 1.01 [95% confidence interval &#8722;0.00 to 2.03, p&#8201;=&#8201;0.05]. There was heterogeneity in this endpoint (df&#8201;=&#8201;7, p&#8201;&lt;&#8201;0.00001, I2&#8201;=&#8201;95%).LimitationsOnly published data. Studies pooled were mainly small, non-randomized trials.
Conclusion:
Sleep apnea treatment with CPAP improves levels of inflammatory markers.</description>
        <link>http://www.journal-inflammation.com/content/10/1/13</link>
                <dc:creator>Aaron Baessler</dc:creator>
                <dc:creator>Rashid Nadeem</dc:creator>
                <dc:creator>Michael Harvey</dc:creator>
                <dc:creator>Essam Madbouly</dc:creator>
                <dc:creator>Amna Younus</dc:creator>
                <dc:creator>Hassan Sajid</dc:creator>
                <dc:creator>Jawed Naseem</dc:creator>
                <dc:creator>Asma Asif</dc:creator>
                <dc:creator>Hasnain Bawaadam</dc:creator>
                <dc:source>Journal of Inflammation 2013, null:13</dc:source>
        <dc:date>2013-03-22T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-9255-10-13</dc:identifier>
                                <prism:require>/content/figures/1476-9255-10-13-toc.gif</prism:require>
                <prism:publicationName>Journal of Inflammation</prism:publicationName>
        <prism:issn>1476-9255</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2013-03-22T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
